Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
allontherapeutics.com

See what CB Insights has to offer

Stage

Acquired | Acquired

Total Raised

$2.5M

Valuation

$0000 

About Allon Therapeutics

Allon Therapeutics Inc. is a clinical-stage biotechnology company developing treatments for major neurodegenerative conditions. Allon has 3 Phase II human efficacy trials underway pursuing three large underserved markets: Alzheimer's disease, schizophrenia and cognitive impairment.The Company is listed on the Toronto Stock Exchange under the trading symbol "NPC" (Neuroprotection CompanyTM) and based in Vancouver.

Allon Therapeutics Headquarter Location

1168 Hamilton Street Suite 506

Vancouver, British Columbia, V6B 2S2,

Canada

Latest Allon Therapeutics News

Blood-Brain Barrier Market Size to Reach USD 7.40 Billion in 2028 | Rising Adoption of Advanced Techniques for Treating Acute Neurological Disorders are Factors Fueling Industry Growth, says Emergen Research

Apr 22, 2021

| Rising Adoption of Advanced Techniques for Treating Acute Neurological Disorders are Factors Fueling Industry Growth, says Emergen Research Key players operating in the Blood-Brain Barrier market are Allon Therapeutics, Inc., Angiochem Inc., Armagen Technologies, Inc., Bristol-Myers Squibb, BiOasis Technologies, Inc., Sanofi Genzyme, CarThera, Cephalon Inc., Nanomerics, and F. Hoffman La-Roche AG. April 22, 2021 15:16 ET Surrey, CANADA Vancouver, British Columbia, April 22, 2021 (GLOBE NEWSWIRE) -- The global blood-brain barrier market size is expected to reach USD 7.40 Billion in 2028 and register a steady CAGR during the forecast period, according to latest analysis by Emergen Research. Growing awareness regarding neurological disorders, increasing healthcare expenditure, advancements in medical technology, and increasing investment in blood-brain barrier technology development are some key factors driving market revenue growth. Blood-brain barrier plays an essential role in protecting the brain from harmful compounds and blood-borne disorders. It blocks the flow of compounds from circulatory systems to the Cerebrospinal Fluid (CSF) or brain by exchanging particular components controlled by BBB or blood CSF barrier. This makes treatment for brain disorders complex due to the specialized uptake of drugs by the blood-brain barrier. Claim Your FREE Sample Copy with Table of content@ https://www.emergenresearch.com/request-sample/633 Recent advancements in drug delivery techniques enable drugs to be transferred directly to cerebrospinal fluids. There are several approaches to create a passage for delivering drugs to the brain such as passive diffusion and bispecific antibody RMT approach, Trojan horse approach, and increasing permeability. In Trojan horse approach, the drug is merged to a molecule that is able to cross the blood-brain barrier through a transporter protein. Some Key Findings From the Report: Key players operating in the market are Allon Therapeutics, Inc., Angiochem Inc., Armagen Technologies, Inc., Bristol-Myers Squibb, BiOasis Technologies, Inc., Sanofi Genzyme, CarThera, Cephalon Inc., Nanomerics, and F. Hoffman La-Roche AG. In Feb 2021, Denali Therapeutics completed a phase 1 trial of a broad portfolio of product candidates that are engineered to cross the blood-brain barrier for neurodegenerative diseases. Increasing permeability segment is expected to register a faster revenue CAGR as compared to other technology segments throughout the forecast period. This can be attributed to rising focus on research activities for treatment of many neurological and central nervous system disorders. North America accounted for a 32.3% revenue share in the global market in 2020. Major prevalence of Hunter’s Syndrome and Alzheimer's Disease, and growing adoption of advanced techniques for treating acute neurological disorders are major factors driving revenue growth of the market in this region. Check Our Prices@ https://www.emergenresearch.com/select-license/633 For the purpose of this report, Emergen Research has segmented the global blood-brain barrier (BBB) market based on application, technology, end-use, and by region: Application Outlook (Revenue, USD Billion; 2018–2028) Alzheimer’s Disease Bispecific Antibody RMT Approach Hospitals

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Allon Therapeutics Patents

Allon Therapeutics has filed 2 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/18/2010

12/4/2012

Autoimmune diseases, Proteins, Transcription factors, Piperidines, Syndromes

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

2/18/2010

00/00/0000

Grant Date

12/4/2012

00/00/0000

Title

Subscribe to see more

Related Topics

Autoimmune diseases, Proteins, Transcription factors, Piperidines, Syndromes

Subscribe to see more

Status

Grant

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.